#Amgen

The Accelerating Cancer Cures Research Symposium fosters communication and collaboration between researchers in industry and academia.

The drug also showed promise for colorectal and other cancers, but it might work better in combination regimens.

MRTX849 shrank tumors in half of lung cancer patients with a common but difficult to target mutation.

First KRAS targeted therapy shows promise for lung and colon cancer

Half of study participants treated with AMG 510 saw their tumors shrink, and only one experienced disease progression.

I understand how people dealing with a cancer diagnosis are incredibly overwhelmed with information.

AMG 510 shrank tumors in half of lung cancer patients with a mutation thought to be “undruggable.”

Multiple immune cell types must be present in tumors for checkpoint inhibitor therapies to be effective.